BiotechTube

AFM28

Phase 1Terminated
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Acute Myeloid Leukemia

Conditions

Acute Myeloid Leukemia

Trial Timeline

Mar 21, 2023 → Jun 13, 2025

NCT ID
NCT05817058

About AFM28

AFM28 is a phase 1 stage product being developed by Affimed for Acute Myeloid Leukemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT05817058. Target conditions include Acute Myeloid Leukemia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05817058Phase 1Terminated

Competing Products

20 competing products in Acute Myeloid Leukemia

See all competitors
ProductCompanyStageHype Score
TRV130 1.5 mg + TRV130 3 mg + TRV130 4.5 mg + Morphine 10 mg + PlaceboTrevenaPhase 1
25
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
44
Oliceridine + Placebo + MorphineTrevenaPhase 3
69
Oliceridine + Placebo + MorphineTrevenaPhase 3
69
TRV130TrevenaPhase 3
69
TRV130 + Morphine + PlaceboTrevenaPhase 2
44
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenCSPC Pharmaceutical Group LimitedPhase 2
51
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
51
SPT-07A injectionSinopharmPhase 3
76
PRGN-3006 T CellsPrecigenPhase 1
28
BisantreneRace OncologyPhase 2
44
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridineRace OncologyPhase 1
25
Bisantrene + Fludarabine + ClofarabineRace OncologyPhase 2
44
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
33
ZN-d5Zentalis PharmaceuticalsPhase 1
25
VIP943 (QW) + VIP943 (BIW)Vincerx PharmaPhase 1
25
LY2523355Eli LillyPhase 1
33
TomivosertibeFFECTOR TherapeuticsPhase 1
25
gemtuzumab ozogamycinChugai PharmaceuticalPhase 3
77
YH14659 + clopidogrel & aspirinYuhanPhase 1
33

Other Products from Affimed

AFM13Phase 2
44
AFM13Phase 2
44
AFM24 + SNK01Phase 1/2
33
AFM24 + Atezolizumab 840 MG in 14 ML InjectionPhase 1/2
33
14 mg AFM24 + 40 mg AFM24 + 80 mg AFM24 + 160 mg AFM24 + 320 mg AFM24 + 480 mg AFM24 + 720 mg AFM24Phase 1/2
33